

**Supplementary Table 22.** Oncogenic / likely oncogenic *MET* TKD mutations in RCC compared to those detected in NSCLC in cohort #1.

<b>MET residue</b>	<b>MET TKD mutations in RCC (N=35)</b>	<b>MET TKD mutations in NSCLC (N=47)</b>	<b>P</b>
H1094X	5 (14.3%)	13 (27.7%)	0.11
Y1230X	10 (28.6%)	7 (14.9%)	0.17
M1250X	8 (22.9%)	1 (2.1%)	<b>0.004</b>
D1228X	1(2.9%)	16 (34.1%)	<b>0.006</b>
V1092X	4 (11.4%)	0	-
F1200X	3 (8.6%)	1 (2.1%)	-
V1220X	1 (2.9%)	3 (6.4%)	-
H1106X	0	1 (2.1%)	-
L1195X	3 (8.4%)	2 (4.3%)	-
V1188X	0	1 (2.1%)	-
N1100X	0	1 (2.1%)	-
H1235X	0	1 (2.1%)	-

Abbreviations: NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma.

Fisher test was performed only when were present at least 5 cases harboring the specific *MET* TKD mutation in at least one of the tumor type (NSCLC or RCC) compared.